Dana Rathkopf
Overview
Explore the profile of Dana Rathkopf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
3535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...
2.
Francini E, Agarwal N, Castro E, Cheng H, Chi K, Clarke N, et al.
Eur Urol
. 2024 Sep;
87(1):29-46.
PMID: 39306478
Background And Objective: Recently, research on treatment intensification has gathered momentum, and three novel therapy combinations were approved for metastatic castration-resistant prostate cancer (mCRPC). This systematic review summarizes the current...
3.
Lenis A, Ravichandran V, Brown S, Alam S, Katims A, Truong H, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3894-3903.
PMID: 38949888
Purpose: Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and response to immune...
4.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv
. 2024 Apr;
PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
5.
McKay R, Xie W, Yang X, Acosta A, Rathkopf D, Laudone V, et al.
Cancer
. 2024 Jan;
130(9):1629-1641.
PMID: 38161319
Background: Patients with localized, unfavorable intermediate-risk and high-risk prostate cancer have an increased risk of relapse after radical prostatectomy (RP). The authors previously reported on part 1 of this phase...
6.
Zhao J, Antonarakis E, Cheng H, George D, Aggarwal R, Riedel E, et al.
Br J Cancer
. 2023 Nov;
130(1):53-62.
PMID: 37980367
Background: CC-115, a dual mTORC1/2 and DNA-PK inhibitor, has promising antitumour activity when combined with androgen receptor (AR) inhibition in pre-clinical models. Methods: Phase 1b multicentre trial evaluating enzalutamide with...
7.
Harrold E, Foote M, Rousseau B, Walch H, Kemel Y, Richards A, et al.
Nat Med
. 2023 Oct;
29(10):2458-2463.
PMID: 37845474
Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB). The ability of ICB to prevent dMMR malignant or pre-malignant neoplasia development in patients with...
8.
Rencsok E, Slopen N, Autio K, Morgans A, McSwain L, Barata P, et al.
Qual Life Res
. 2023 Jul;
32(11):3209-3221.
PMID: 37410340
Purpose: To assess differences in baseline and longitudinal quality of life among Black and White individuals in the US with advanced prostate cancer. Methods: Secondary analysis of data from the...
9.
Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, et al.
Eur J Cancer
. 2023 Apr;
185:178-215.
PMID: 37003085
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to...
10.
Chi K, Rathkopf D, Smith M, Efstathiou E, Attard G, Olmos D, et al.
J Clin Oncol
. 2023 Mar;
41(18):3339-3351.
PMID: 36952634
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase...